Axonics, Inc. (AXNX) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Medical - Devices industria. La empresa tiene su sede en Irvine, CA, United States. El CEO actual es Raymond W. Cohen.
AXNX tiene fecha de IPO 2018-10-31, 797 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $3.63B.
Axonics, Inc. is a medical technology company that develops and commercializes sacral neuromodulation (SNM) systems to treat bladder and bowel dysfunction disorders, including overactive bladder, urinary incontinence, and fecal incontinence. The company's proprietary rechargeable SNM system delivers mild electrical pulses to the sacral nerve to restore normal communication between the bladder, bowel, and brain. In addition to its SNM platform, Axonics offers Bulkamid, a urethral bulking agent for treating female stress urinary incontinence. The company markets its products through a direct sales force and distributor network across the United States, United Kingdom, Germany, the Netherlands, Nordic countries, and other international markets.
